The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 08, 2010
Filed:
Jun. 13, 2007
Warren J. Leonard, Bethesda, MD (US);
Akhilesh Pandey, Pikesville, MD (US);
Amin Al-shami, Bethesda, MD (US);
Rosanne Spolski, Ellicott City, MD (US);
Warren J. Leonard, Bethesda, MD (US);
Akhilesh Pandey, Pikesville, MD (US);
Amin Al-Shami, Bethesda, MD (US);
Rosanne Spolski, Ellicott City, MD (US);
The United States of America as represented by the Department of Health and Human Services, Washington, DC (US);
Whitehead Institute of Biomedical Research, Cambridge, MA (US);
Abstract
Methods are disclosed herein for specifically inducing proliferation of CD4T cells. The methods are of use in treating immunodeficiencies, such as an immunodeficiency produced by infection with an immunodeficiency virus, such as infection with a human immunodeficiency virus (HIV). The methods include contacting isolated mammalian CD4+ T cells with an effective amount of a thymic stromal derived lymphopoietin (TSLP) polypeptide or a therapeutically effective amount of nucleic acid encoding the TSLP polypeptide, thereby inducing proliferation of the T cells. Methods are also disclosed for treating an IgE mediated disorder, such as asthma. The methods include administering to a subject a therapeutically effective amount of a TSLP antagonist. Transgenic mice are also disclosed herein. The somatic and germ cells of these mice include a disrupted thymic stromal lymphopoietin receptor (TSLP) gene, the disruption being sufficient to inhibit the interaction of TSLP with its receptor, and a disrupted γgene, the disruption being sufficient to reduce signaling through the γ. The mice exhibit diminished thymic cellularity. Methods of using these mice for drug screening are also disclosed.